Clinical Trial Update: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating eribulin mesylate in combination with trastuzumab for advanced or recurrent HER2-positive breast cancer completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-03-30